DE3429551A1 - Pharmazeutische zubereitung, die ein glycoprotein enthaelt - Google Patents
Pharmazeutische zubereitung, die ein glycoprotein enthaeltInfo
- Publication number
- DE3429551A1 DE3429551A1 DE19843429551 DE3429551A DE3429551A1 DE 3429551 A1 DE3429551 A1 DE 3429551A1 DE 19843429551 DE19843429551 DE 19843429551 DE 3429551 A DE3429551 A DE 3429551A DE 3429551 A1 DE3429551 A1 DE 3429551A1
- Authority
- DE
- Germany
- Prior art keywords
- glycoprotein
- activity
- administered
- pharmaceutical preparation
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000288 Glycoproteins Proteins 0.000 title claims description 224
- 102000003886 Glycoproteins Human genes 0.000 title claims description 224
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 43
- 230000000694 effects Effects 0.000 claims description 102
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 32
- 230000001965 increasing effect Effects 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 20
- 230000017531 blood circulation Effects 0.000 claims description 18
- 230000000202 analgesic effect Effects 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 230000001754 anti-pyretic effect Effects 0.000 claims description 14
- 150000003180 prostaglandins Chemical class 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 210000003743 erythrocyte Anatomy 0.000 claims description 13
- 230000004060 metabolic process Effects 0.000 claims description 13
- -1 analgesic Substances 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 10
- 201000001474 proteinuria Diseases 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 230000036772 blood pressure Effects 0.000 claims description 9
- 241000221198 Basidiomycota Species 0.000 claims description 8
- 241000222356 Coriolus Species 0.000 claims description 8
- 230000002785 anti-thrombosis Effects 0.000 claims description 8
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 239000003513 alkali Substances 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 239000003435 antirheumatic agent Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000002221 antipyretic Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 67
- 241001465754 Metazoa Species 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 230000001629 suppression Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- 230000002354 daily effect Effects 0.000 description 23
- 239000004480 active ingredient Substances 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 239000001963 growth medium Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 15
- 201000005577 familial hyperlipidemia Diseases 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 230000002776 aggregation Effects 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 206010003246 arthritis Diseases 0.000 description 10
- 210000002683 foot Anatomy 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 102000000853 LDL receptors Human genes 0.000 description 8
- 108010001831 LDL receptors Proteins 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 230000001944 accentuation Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 208000031225 myocardial ischemia Diseases 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- 208000005189 Embolism Diseases 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 206010029164 Nephrotic syndrome Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 208000001435 Thromboembolism Diseases 0.000 description 7
- 239000000701 coagulant Substances 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000036461 convulsion Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 208000009928 nephrosis Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 208000018152 Cerebral disease Diseases 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 6
- 206010018691 Granuloma Diseases 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000000548 hind-foot Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010028347 Muscle twitching Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 208000006268 Sarcoma 180 Diseases 0.000 description 4
- 241000222355 Trametes versicolor Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000027950 fever generation Effects 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000001630 jejunum Anatomy 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 231100001027 nephrosis Toxicity 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940039750 aconitine Drugs 0.000 description 2
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003218 coronary vasodilator agent Substances 0.000 description 2
- 229940117173 croton oil Drugs 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000035780 glucosuria Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 description 1
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- WOHLSTOWRAOMSG-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole Chemical compound C1=CC=C2SCNC2=C1 WOHLSTOWRAOMSG-UHFFFAOYSA-N 0.000 description 1
- BWIHJLOBZMKPKS-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)pyrimidine Chemical compound N1C=CC(C=2N=CC=CN=2)=N1 BWIHJLOBZMKPKS-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- RYSMHWILUNYBFW-GRIPGOBMSA-N 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](N)[C@H]1O RYSMHWILUNYBFW-GRIPGOBMSA-N 0.000 description 1
- BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 description 1
- PTGXAUBQBSGPKF-UHFFFAOYSA-N 4-[1-hydroxy-2-(4-phenylbutan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)CCC1=CC=CC=C1 PTGXAUBQBSGPKF-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000974482 Aricia saepiolus Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- ZVXBAHLOGZCFTP-UHFFFAOYSA-N Efloxate Chemical compound C=1C(OCC(=O)OCC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZVXBAHLOGZCFTP-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000116710 Ferula foetidissima Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- YEKQSSHBERGOJK-UHFFFAOYSA-N Pyricarbate Chemical compound CNC(=O)OCC1=CC=CC(COC(=O)NC)=N1 YEKQSSHBERGOJK-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003455 buphenine Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 229960005003 carbocromen Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960000729 cyclandelate Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003859 efloxate Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- KRQAMFQCSAJCRH-UHFFFAOYSA-N hexobendine Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCCN(C)CCN(C)CCCOC(=O)C=2C=C(OC)C(OC)=C(OC)C=2)=C1 KRQAMFQCSAJCRH-UHFFFAOYSA-N 0.000 description 1
- 229960002212 hexobendine Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- HHIVCXLCMPHUSC-UHFFFAOYSA-N hydron;1h-indol-1-ium;sulfate Chemical compound OS(O)(=O)=O.C1=CC=C2NC=CC2=C1 HHIVCXLCMPHUSC-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000000408 hypertonic glucose solution Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960004819 isoxsuprine Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 231100001225 mammalian toxicity Toxicity 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001989 prenylamine Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 description 1
- 229960004986 pyritinol Drugs 0.000 description 1
- ZLQMRLSBXKQKMG-UHFFFAOYSA-N rauniticine Natural products COC(=O)C1=CC2CC3N(CCc4c3[nH]c5ccccc45)CC2C(C)O1 ZLQMRLSBXKQKMG-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940083085 thiazide derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58147233A JPS6045526A (ja) | 1983-08-11 | 1983-08-11 | 虚血性心疾患改善剤 |
| JP58147234A JPS6045528A (ja) | 1983-08-11 | 1983-08-11 | 虚血性脳疾患改善剤 |
| JP58147235A JPS6045527A (ja) | 1983-08-11 | 1983-08-11 | 血圧降下剤 |
| JP58147239A JPS6045524A (ja) | 1983-08-11 | 1983-08-11 | 抗炎症剤 |
| JP58147241A JPS6045533A (ja) | 1983-08-11 | 1983-08-11 | プロスタグランジン調節剤 |
| JP58147236A JPS6045529A (ja) | 1983-08-11 | 1983-08-11 | 抗血栓症剤 |
| JP58147232A JPS6045525A (ja) | 1983-08-11 | 1983-08-11 | 抗リウマチ剤 |
| JP58147237A JPS6045523A (ja) | 1983-08-11 | 1983-08-11 | 解熱鎮痛剤 |
| JP58147240A JPS6045530A (ja) | 1983-08-11 | 1983-08-11 | ネフロ−ゼ症候群改善剤 |
| JP58147238A JPS6045531A (ja) | 1983-08-11 | 1983-08-11 | 抗高脂血症剤 |
| JP58147231A JPS6045532A (ja) | 1983-08-11 | 1983-08-11 | 血糖降下剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3429551A1 true DE3429551A1 (de) | 1985-02-21 |
| DE3429551C2 DE3429551C2 (enExample) | 1989-09-21 |
Family
ID=27582198
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3448152A Expired DE3448152C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448154A Expired DE3448154C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448155A Expired DE3448155C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448148A Expired DE3448148C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE19843429551 Granted DE3429551A1 (de) | 1983-08-11 | 1984-08-10 | Pharmazeutische zubereitung, die ein glycoprotein enthaelt |
| DE3448149A Expired - Fee Related DE3448149C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448151A Expired DE3448151C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448144A Expired DE3448144C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448150A Expired DE3448150C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448145A Expired DE3448145C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448153A Expired DE3448153C2 (enExample) | 1983-08-11 | 1984-08-10 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3448152A Expired DE3448152C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448154A Expired DE3448154C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448155A Expired DE3448155C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448148A Expired DE3448148C2 (enExample) | 1983-08-11 | 1984-08-10 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3448149A Expired - Fee Related DE3448149C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448151A Expired DE3448151C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448144A Expired DE3448144C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448150A Expired DE3448150C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448145A Expired DE3448145C2 (enExample) | 1983-08-11 | 1984-08-10 | |
| DE3448153A Expired DE3448153C2 (enExample) | 1983-08-11 | 1984-08-10 |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US4820689A (enExample) |
| DE (11) | DE3448152C2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0353861A1 (en) * | 1988-06-30 | 1990-02-07 | Kureha Kagaku Kogyo Kabushiki Kaisha | Angiogenesis inhibitor |
| EP0725077A1 (en) * | 1995-02-06 | 1996-08-07 | Kureha Chemical Industry Co., Ltd. | Novel glycoproteins, process for preparation thereof, and pharmaceutical composition |
| EP1918363A4 (en) * | 2005-07-28 | 2011-02-02 | Nikken Sohonsha Corp | BUTTERFLY ROOT STAMM, EXTRACT THEREOF AND USE THEREOF |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3639561A1 (de) * | 1986-11-20 | 1988-06-01 | Baumann Hanno | Verfahren zur herstellung von nicht-thrombogenen substraten |
| DE3942081A1 (de) * | 1989-12-20 | 1991-06-27 | Behringwerke Ag | Mittel zur verbesserung der wiederfindung von annexinen |
| US5393742A (en) * | 1990-08-30 | 1995-02-28 | Mect Corporation | Preparation for treating renal disease |
| JPH0737990B2 (ja) * | 1990-10-12 | 1995-04-26 | 寳酒造株式会社 | 糖類の標識方法及び糖類標識用キット |
| US5374714A (en) * | 1992-11-30 | 1994-12-20 | Yang; Mable M. P. | Purified coriolus versicolor polypeptide complex |
| DE69423806T2 (de) * | 1993-01-22 | 2000-08-17 | Kanegafuchi Chemical Ind | Therapeutisches Agens für NIDDM |
| CN1157221C (zh) * | 1994-06-30 | 2004-07-14 | 明治乳业株式会社 | 保健组合物 |
| US6379714B1 (en) * | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
| WO2001056589A2 (en) * | 2000-01-31 | 2001-08-09 | Tadashi Goino | Physiologically active compositions of basidiomycotina and araliaceae extracts |
| WO2002098440A1 (en) * | 2001-06-01 | 2002-12-12 | Ajinomoto Co., Inc. | Drugs for diabetes |
| US7048932B2 (en) * | 2002-05-22 | 2006-05-23 | The Chinese University Of Hong Kong | Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor |
| JP4587442B2 (ja) * | 2004-02-12 | 2010-11-24 | 株式会社クレハ | 新規な高脂血症治療剤および食品 |
| KR100852479B1 (ko) | 2007-01-26 | 2008-08-18 | 대구대학교 산학협력단 | 혈당강하 효과를 갖는 운지버섯 유래 다당체 및 그 제조방법 |
| CN105597080A (zh) * | 2016-01-29 | 2016-05-25 | 程潜 | 一种用于治疗尿毒症和尿蛋白的药物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2659808B2 (de) * | 1976-01-01 | 1979-08-02 | Kureha Kagaku Kogyo K.K., Tokio | Proteingebundene Polysaccharide und deren Verwendung zur Bekämpfung von Tumoren |
| JPS57134496A (en) | 1981-02-10 | 1982-08-19 | Kureha Chem Ind Co Ltd | Novel conjugated glycoprotein |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3929994A (en) * | 1969-05-20 | 1975-12-30 | Roussel Uclaf | Anti-inflammatory glycoprotein compositions and method of use |
| JPS5290614A (en) * | 1975-12-18 | 1977-07-30 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor substance |
| JPS536412A (en) * | 1976-07-07 | 1978-01-20 | Kureha Chem Ind Co Ltd | Preparation of n-containing polysaccharides |
| JPS536413A (en) * | 1976-07-07 | 1978-01-20 | Kureha Chem Ind Co Ltd | Preparation of n-containing polysaccharides |
| JPS5315495A (en) * | 1976-07-22 | 1978-02-13 | Kureha Chem Ind Co Ltd | Preparation of polysaccharides |
| US4268505A (en) * | 1978-04-13 | 1981-05-19 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition comprising a nitrogen-containing polysaccharide and an antibiotic agent, and a method of treating an infectious disease therewith |
| JPS5851263B2 (ja) * | 1979-07-16 | 1983-11-15 | コニカ株式会社 | 熱ロ−ラ型定着装置 |
| JPS5614276A (en) * | 1979-07-17 | 1981-02-12 | Toshiba Corp | Flash fixing device |
| JPS5639288A (en) * | 1979-09-07 | 1981-04-14 | Mitsui Constr | Drilling machine for locking bolt for pit |
| JPH05136322A (ja) * | 1991-11-11 | 1993-06-01 | Mitsubishi Electric Corp | 半導体装置 |
-
1984
- 1984-08-10 DE DE3448152A patent/DE3448152C2/de not_active Expired
- 1984-08-10 DE DE3448154A patent/DE3448154C2/de not_active Expired
- 1984-08-10 DE DE3448155A patent/DE3448155C2/de not_active Expired
- 1984-08-10 DE DE3448148A patent/DE3448148C2/de not_active Expired
- 1984-08-10 DE DE19843429551 patent/DE3429551A1/de active Granted
- 1984-08-10 DE DE3448149A patent/DE3448149C2/de not_active Expired - Fee Related
- 1984-08-10 DE DE3448151A patent/DE3448151C2/de not_active Expired
- 1984-08-10 DE DE3448144A patent/DE3448144C2/de not_active Expired
- 1984-08-10 DE DE3448150A patent/DE3448150C2/de not_active Expired
- 1984-08-10 DE DE3448145A patent/DE3448145C2/de not_active Expired
- 1984-08-10 DE DE3448153A patent/DE3448153C2/de not_active Expired
-
1986
- 1986-08-22 US US06/898,900 patent/US4820689A/en not_active Expired - Fee Related
-
1988
- 1988-12-16 US US07/285,664 patent/US5008243A/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2659808B2 (de) * | 1976-01-01 | 1979-08-02 | Kureha Kagaku Kogyo K.K., Tokio | Proteingebundene Polysaccharide und deren Verwendung zur Bekämpfung von Tumoren |
| JPS57134496A (en) | 1981-02-10 | 1982-08-19 | Kureha Chem Ind Co Ltd | Novel conjugated glycoprotein |
Non-Patent Citations (5)
| Title |
|---|
| Firmenschrift der Ain ais dem Jahr 1977, Outline of PSK, S.28-30 |
| Firmenschrift der Ain aus dem Jahr 1977, Outline of PSK, S.28-30 |
| Firmenschrift der Ain aus dem Jahr 1977, Qutline of PKS, S. 28-30 |
| Firmenschrift der Ain aus dem Jahr 1977, Qutline of PSK, S.28-30 |
| JP Abstract 57-13 44 96 Firmenschrift, Kureha, Chemical Industry Co., Ltd., Tokyo, 1977, Outline of PSK, S.28-30 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0353861A1 (en) * | 1988-06-30 | 1990-02-07 | Kureha Kagaku Kogyo Kabushiki Kaisha | Angiogenesis inhibitor |
| EP0725077A1 (en) * | 1995-02-06 | 1996-08-07 | Kureha Chemical Industry Co., Ltd. | Novel glycoproteins, process for preparation thereof, and pharmaceutical composition |
| EP1918363A4 (en) * | 2005-07-28 | 2011-02-02 | Nikken Sohonsha Corp | BUTTERFLY ROOT STAMM, EXTRACT THEREOF AND USE THEREOF |
Also Published As
| Publication number | Publication date |
|---|---|
| US5008243A (en) | 1991-04-16 |
| DE3448150C2 (enExample) | 1989-11-02 |
| DE3448154C2 (enExample) | 1989-11-02 |
| US4820689A (en) | 1989-04-11 |
| DE3448152C2 (enExample) | 1989-11-02 |
| DE3448155C2 (enExample) | 1989-11-02 |
| DE3429551C2 (enExample) | 1989-09-21 |
| DE3448153C2 (enExample) | 1989-11-02 |
| DE3448144C2 (enExample) | 1989-10-05 |
| DE3448149C2 (enExample) | 1990-01-04 |
| DE3448151C2 (enExample) | 1989-11-02 |
| DE3448145C2 (enExample) | 1989-09-21 |
| DE3448148C2 (enExample) | 1989-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3429551A1 (de) | Pharmazeutische zubereitung, die ein glycoprotein enthaelt | |
| DE69627042T2 (de) | Isocumarinderivate und deren verwendung in medikamenten | |
| DE69323185T2 (de) | Proteinkinase c-inhibitor | |
| DE3827623A1 (de) | Verfahren zur herstellung von getrocknetem regenwurmpulver und antihyperlipaemische, antidiabetische, antihypertonische und antihypotonische zubereitungen, die getrocknetes regenwurmpulver als aktiven bestandteil enthalten | |
| DD235450B1 (de) | Verfahren zur herstellung neuer 1-(2-hydroxyaryl)-alkan-1-on-oxime | |
| DE69327284T2 (de) | Neutrale Lipide aus dem Endosperm von Coix lacryma jobi und sie enthaltende Zusammensetzungen | |
| DE69811500T2 (de) | Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum | |
| EP0038343B1 (de) | Substituierte oxocarbonsäuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel | |
| DE3872234T2 (de) | Zyklische kohlenwasserstoffe mit aminoalkyl-seitenkette. | |
| US4534975A (en) | Pharmaceutical composition containing 24,25-dihydroxycholecalciferol in methods of treatment | |
| DE2911353C2 (enExample) | ||
| EP0856513B1 (de) | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione | |
| DE3875324T2 (de) | Dl-5-((2-benzyl-3,4-dihydro-2h-benzopyran-6-yl)methyl)thiazolidin-2,4-dion als antiatherosklerosemittel. | |
| DE2625222A1 (de) | 1,3-dithiolan-2-yliden-malonsaeureesterderivate, verfahren zu ihrer herstellung und arzneimittel | |
| DE60220799T2 (de) | Hypoglykämisches mittel | |
| DE69017825T2 (de) | Heilverfahren von Lebererkrankungen mit Verwendung von Pyrrol-Chinolin-Chinone-Triester und neue Pyrrol-Chinolin-Chinone-Triester. | |
| DE3030892A1 (de) | Mittel zur steuerung der herstellung und des stoffwechsels von prostaglandin in saeugetieren | |
| DE69300945T2 (de) | Fettstoffwechsel verbessernde Zusammensetzung. | |
| DE3417573A1 (de) | Arzneimittel mit lipoxygenase hemmender wirkung | |
| DE69306770T2 (de) | Hydrazid-derivate von 3,4-dihydro-2h-1-benzopyranen | |
| DE2038836C3 (de) | Arzneimittel | |
| DE60004353T2 (de) | Derivate der gymnemischen säure, verfahren zu ihrer herstellung und ihre verwendung als medikamente | |
| EP0121856A2 (de) | Verwendung von Pyrazolonderivaten bei der Bekämpfung des Wachstums von Tumorzellen und der Metastasenbildung, Arzneimittel hierfür und Verfahren zu deren Herstellung | |
| DE2708666C3 (de) | Arzneimittel mit immunoregulativer und antiphlogistischer Wirkung | |
| DE2515142B2 (de) | Oral verabfolgbare mittel zur senkung des lipid- und cholesterin- spiegels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8128 | New person/name/address of the agent |
Representative=s name: KADOR, U., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 800 |
|
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3448153 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3448153 |
|
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3448151 Format of ref document f/p: P Ref country code: DE Ref document number: 3448152 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3448151 Ref country code: DE Ref document number: 3448152 |
|
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3448149 Format of ref document f/p: P Ref country code: DE Ref document number: 3448148 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3448148 Ref country code: DE Ref document number: 3448149 |
|
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3448145 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3448145 |
|
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3448154 Format of ref document f/p: P Ref country code: DE Ref document number: 3448144 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3448144 Ref country code: DE Ref document number: 3448154 |
|
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3448150 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3448150 |
|
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3448155 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3448155 |
|
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3448147 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3448147 |
|
| AH | Division in |
Ref country code: DE Ref document number: 3448150 Format of ref document f/p: P Ref country code: DE Ref document number: 3448152 Format of ref document f/p: P Ref country code: DE Ref document number: 3448149 Format of ref document f/p: P Ref country code: DE Ref document number: 3448153 Format of ref document f/p: P Ref country code: DE Ref document number: 3448145 Format of ref document f/p: P Ref country code: DE Ref document number: 3448148 Format of ref document f/p: P Ref country code: DE Ref document number: 3448151 Format of ref document f/p: P Ref country code: DE Ref document number: 3448155 Format of ref document f/p: P Ref country code: DE Ref document number: 3448144 Format of ref document f/p: P Ref country code: DE Ref document number: 3448147 Format of ref document f/p: P Ref country code: DE Ref document number: 3448154 Format of ref document f/p: P |
|
| D2 | Grant after examination | ||
| AH | Division in |
Ref country code: DE Ref document number: 3448144 Format of ref document f/p: P |
|
| AH | Division in |
Ref country code: DE Ref document number: 3448151 Format of ref document f/p: P Ref country code: DE Ref document number: 3448154 Format of ref document f/p: P Ref country code: DE Ref document number: 3448152 Format of ref document f/p: P Ref country code: DE Ref document number: 3448150 Format of ref document f/p: P Ref country code: DE Ref document number: 3448153 Format of ref document f/p: P Ref country code: DE Ref document number: 3448155 Format of ref document f/p: P |
|
| AH | Division in |
Ref country code: DE Ref document number: 3448149 Format of ref document f/p: P |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |